Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Focused Ultrasound Systems Market Size & Share 2026-2035
Report ID: GMI14366
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Focused Ultrasound Systems Market
Get a free sample of this reportWhat are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.

Focused Ultrasound Systems Market Size
The focused ultrasound systems market was valued at USD 355.3 million in 2025, is expected to reach USD 393.1 million in 2026, and is projected to advance at a CAGR of 9.7% from 2026 to 2035, reaching USD 907.6 million by 2035.
Focused Ultrasound Systems Market Key Takeaways
Market Leader: Insightec led with over 35.2% market share in 2025.
Leading Players: Top 5 players in this market include Insightec, Chongqing Haifu Medical Technology, EDAP TMS, Profound Medical, Sonablate, which collectively held a market share of 63.1% in 2025.
The focused ultrasound systems market is moving from specialist adoption toward broader institutional deployment as clinical evidence, regulatory access, and reimbursement pathways improve the business case for incision-free treatment programs. Capital purchasing remains selective, however, because clinical throughput, imaging integration, and multidisciplinary expertise determine whether a system can achieve sustainable utilization.
GMI Analyst View
Our engagement with health system procurement specialists and clinical technology leaders indicates that the focused ultrasound systems market generated USD 265.4 million in 2022. Expansion from that historic reference reflects an accelerating capital-equipment refresh cycle shaped by neurological and oncological clearances, indicating that installed-base momentum is extending beyond early-adopter academic programs into wider institutional deployment.
Focused Ultrasound Systems Market Trends, Growth Drivers & GMI Forecast Outlook
Focused ultrasound demand is increasingly shaped by the intersection of clinical eligibility, site economics, and the ability to deliver treatment outside conventional surgical pathways. Established therapeutic ablation supports near-term placements, while LIFU research and neuromodulation programs widen the longer-term opportunity set.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
The disease burden across neurological, urological, and gynecological indications creates a durable clinical foundation for focused ultrasound investment. Uterine fibroids affected approximately 119.5 million people globally in 2021, underscoring the scale of the patient population for which uterine-preserving, non-incisional treatment pathways may be clinically relevant [3]Wu C, Zhou LH, Chen R, Li H, Li J, Guo F, Li R, Zhou H, Huang J. "The epidemiology of uterine fibroids: global disease burden from 1990 to 2021 and future trend predictions." pmc.ncbi.nlm.nih.gov. For providers, the commercial significance lies not simply in prevalence, but in the ability to concentrate eligible cases at centers that can establish repeatable referral and treatment workflows.
Reimbursement progression changes the timing of capital decisions. When procedural payment becomes more predictable, hospitals can assess focused ultrasound against surgery, imaging, and robotic investments on a clearer utilization basis. This is particularly consequential for urology and movement-disorder programs, where clinical champions require an economic pathway that supports team training, procedure scheduling, and technology maintenance.
The appeal of incision-free therapy also extends to health-system capacity management. Focused ultrasound can redirect selected treatment pathways away from operating rooms and toward image-guided care settings, provided that patient selection, imaging access, and multidisciplinary coordination are established. That operational fit gives the modality relevance in systems seeking to preserve clinical outcomes while reducing recovery-related resource use.
Key Restraints
Capital intensity remains the central constraint on adoption because an MR-guided program requires more than equipment procurement. Site preparation, imaging access, procedure consumables, service support, and the opportunity cost of MRI time all affect the economics of a new program. As a result, purchasing is concentrated among providers that can aggregate sufficient case volume and coordinate capital planning across neurology, urology, gynecology, radiology, and hospital administration.
The workforce requirement compounds that financial hurdle. Focused ultrasound programs depend on clinical leadership, imaging expertise, treatment planning discipline, and ongoing procedure volume to maintain proficiency. Facilities that lack established interventional imaging infrastructure can face longer launch periods, limiting the conversion of clinical interest into active system utilization.
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
GMI Analyst View
We see the decisive market tension as a channel-capacity issue rather than a simple comparison of procedural benefit against equipment cost. Demand can expand faster than trained centers, reimbursement pathways, and coordinated imaging workflows. Suppliers that reduce installation complexity while helping providers build referral and treatment capacity should be best positioned to convert clinical interest into durable equipment utilization.
Focused Ultrasound Systems Market Segment Analysis
By Product
HIFU systems generated USD 270.6 million in 2025 and are expected to account for 60.0% of market revenue by 2035. Their position reflects an established therapeutic footprint across ablation-oriented applications, supported by provider familiarity with clinical workflows in urology, gynecology, neurology, and dermatology. The segment's mix evolves as newer lower-intensity platforms gain relevance, but HIFU retains a substantial role where tissue ablation and procedural versatility remain central to the care model.
By Application
Clinical Applications
Clinical applications generated USD 319.4 million in 2025 and are projected to grow at a 9.8% CAGR (2026-2035). Their scale reflects the current concentration of commercial demand in therapeutic use cases with established treatment protocols and growing reimbursement support. Broader indication coverage also improves the utilization case for hospitals because one platform may serve more than one clinical department.
Uterine Fibroids
Uterine fibroids generated USD 88.5 million in 2025 and are expected to represent 22.0% of market revenue by 2035. Demand is supported by the clinical value of uterine-preserving treatment and by patient preference for alternatives to invasive procedures. Sustained relevance will depend on continued integration into referral pathways and payer recognition of focused ultrasound within women's health programs.
Prostate Cancer
Prostate cancer accounted for 23.9% of focused ultrasound systems market revenue in 2025 and is projected to generate USD 190.6 million by 2035. Focal and whole-gland ablation pathways are strengthening the commercial case for HIFU systems at urology centers seeking to offer function-preserving treatment options. Reimbursement consistency, physician training, and evidence on patient selection will determine how widely these platforms move beyond high-volume specialist institutions.
Essential Tremor
Essential tremor generated USD 63.2 million in 2025 and is projected to advance at a 9.9% CAGR (2026-2035). The application benefits from a well-defined clinical need among patients who do not obtain adequate symptom control through medication. Expansion will be determined by the pace at which treatment centers can establish multidisciplinary movement-disorder pathways and secure reliable procedural access.
Other Clinical Applications
Dermatology, back pain, breast cancer, glaucoma, and other clinical applications broaden the therapeutic relevance of focused ultrasound beyond its leading indications. These areas vary substantially in regulatory maturity, reimbursement access, and care setting, but collectively support supplier interest in platforms that can address multiple anatomical targets and provider specialties. Their progression is particularly important for improving asset utilization at sites that require diverse procedural demand to justify capital investment.
Research Applications
Research applications represented 10.1% of focused ultrasound systems market revenue in 2025 and are projected to generate USD 90.8 million by 2035. Academic institutions, pharmaceutical developers, and translational research groups use these systems to investigate neuromodulation, drug delivery, and therapeutic targeting. The segment has strategic significance because it supplies the clinical evidence and investigator experience that may support future indication expansion.
By End Use
Hospitals generated USD 202.5 million in 2025 and are expected to hold 55.0% of market revenue by 2035. They retain a structural advantage because complex focused ultrasound procedures often require access to advanced imaging, anesthesia support, clinical specialists, and post-procedure monitoring. Multi-department utilization can further strengthen the hospital investment case when platforms serve neurological, urological, and gynecological programs.
Imaging centers accounted for 20.7% of market revenue in 2025 and are projected to generate USD 181.5 million by 2035. Their opportunity expands where ultrasound-guided or modular configurations lower dependence on hospital MRI suites. These settings may become increasingly relevant for procedures with standardized patient pathways and outpatient delivery potential, although reimbursement and referral integration remain essential.
Academic & research institutes generated USD 54.1 million in 2025 and are expected to grow at a 10.4% CAGR (2026-2035). These organizations serve as both end users and evidence-generation centers, particularly for LIFU, drug-delivery, and neurotherapeutic applications. Their partnerships with device developers and pharmaceutical organizations can accelerate protocol development, clinician training, and eventual technology transfer into clinical settings.
Other end use represented 7.0% of market revenue in 2025 and is projected to generate USD 81.7 million by 2035. Ambulatory surgical centers, specialty clinics, and aesthetic practices are relevant where lower-intensity systems and streamlined care pathways reduce the infrastructure burden of deployment. Growth in this channel depends on equipment simplification, provider training, and the commercial viability of office-based treatment models.
GMI Analyst View
We view the product mix as an expansion of the market's commercial architecture rather than a displacement of established ablation systems. HIFU remains anchored in mature therapeutic workflows, while LIFU creates a research-to-clinical pathway in neurological and drug-delivery applications. Suppliers with credible multi-indication platforms can make a stronger utilization argument to institutions evaluating specialized capital equipment.
Focused Ultrasound Systems Market Regional Analysis
North America Focused Ultrasound Systems Market Analysis
North America generated USD 150.6 million in 2025 and is projected to generate USD 345.2 million by 2035. The focused ultrasound systems market in the region benefits from mature academic medical infrastructure, established manufacturer activity, and comparatively developed reimbursement pathways across neurological and urological care. Future growth increasingly depends on extending treatment availability beyond pioneering centers into community hospitals and ambulatory care models.
U.S.
The U.S. generated USD 136.0 million in 2025 and represented 90.3% of North American market revenue. Its leadership reflects dense concentrations of teaching hospitals, interventional imaging infrastructure, and physician education networks capable of supporting specialized programs. The country's opportunity is reinforced by the ongoing broadening of clinical indications and the ability of reimbursement mechanisms to support provider investment planning.
Canada
Canada is projected to grow at a 10.6% CAGR (2026-2035) and is expected to account for 11.5% of North American market revenue by 2035. Regulatory and reimbursement progress can expand access at academic centers, particularly where imaging compatibility and movement-disorder expertise already exist. Adoption is likely to remain concentrated in referral centers before broader clinical networks develop.
Europe Focused Ultrasound Systems Market Analysis
Europe accounted for 22.6% of market revenue in 2025 and is projected to grow at a 9.6% CAGR (2026-2035). Demand is supported by university hospitals, established HIFU use in selected therapeutic areas, and gradually developing national reimbursement structures. Commercial progress remains uneven because procurement and health technology assessment processes differ materially by country.
Germany
Germany generated USD 18.2 million in 2025 and is projected to grow at a 9.7% CAGR (2026-2035). Its well-resourced hospital network and active urology sector support adoption of image-guided ablation technologies. Continued growth will depend on how hospital financing reforms and evidence-based technology assessment affect capital purchasing priorities.
UK
The UK represented 17.4% of European market revenue in 2025 and is projected to generate USD 34.0 million by 2035. NHS commissioning decisions and evidence development at clinical trial sites shape the pace of deployment. System compatibility and the availability of trained clinical teams will influence whether adoption broadens across the country's imaging estate.
France
France generated USD 11.5 million in 2025 and is expected to account for 13.8% of European market revenue by 2035. The country has an established clinical base in prostate treatment and expanding institutional support for neurological applications. National reimbursement clarity can improve hospital confidence in program development by converting clinical demand into an operationally viable treatment pathway.
Italy
Italy's oncology-oriented hospital networks provide a commercial foundation for HIFU applications, particularly where provider interest aligns with advanced treatment programs. Adoption remains dependent on local procurement decisions, clinical evidence, and reimbursement development.
Spain
Spain's potential is supported by specialist hospital networks and interest in non-invasive treatment approaches. Market development will depend on the pace of technology assessment and the ability of suppliers to establish physician-training partnerships.
Netherlands
The Netherlands remains relevant to European focused ultrasound development through clinical research and platform innovation. Its influence exceeds its immediate procurement footprint because research activity can support broader evidence generation and technology refinement.
Asia Pacific Focused Ultrasound Systems Market Analysis
Asia Pacific generated USD 93.1 million in 2025 and is expected to account for 28.8% of market revenue by 2035. The region combines China's established extracorporeal HIFU base with regulated MR-guided adoption in Japan, expanding hospital investment in India, and technologically sophisticated clinical systems in South Korea. This diversity creates multiple routes to growth, ranging from first-time program installations to advanced research placements.
China
China generated USD 47.5 million in 2025 and is projected to generate USD 120.0 million by 2035. The country's large extracorporeal HIFU installed base supports its regional leadership, particularly across oncology and gynecological applications. Hospital modernization, increasing healthcare expenditure, and domestic manufacturing capabilities strengthen the conditions for continued system placements.
Japan
Japan represented 19.1% of Asia Pacific market revenue in 2025 and is projected to grow at an 8.7% CAGR (2026-2035). Its regulatory and reimbursement environment can produce durable adoption once clinical pathways are established. Demand is concentrated in advanced academic and oncology settings where providers can support the procedural discipline required for focused ultrasound programs.
India
India generated USD 7.8 million in 2025 and is projected to grow at a 15.5% CAGR (2026-2035). Rising hospital capital expenditure, greater awareness of non-invasive options, and expanding oncology capacity underpin an early-stage opportunity. Partnerships that combine clinical training, research collaboration, and access to domestic or international platforms will be important to market development.
South Korea
South Korea accounted for 9.1% of Asia Pacific market revenue in 2025 and is projected to generate USD 25.0 million by 2035. The country's advanced hospital infrastructure and medtech ecosystem support both therapeutic HIFU adoption and research-grade system placements. Its clinical trial capabilities may also reinforce its role in evaluating new focused ultrasound applications.
Australia
Australia has an established, though smaller, demand base supported by academic medical centers and clinical interest in neurological and prostate applications. Continued adoption depends on clinical access, reimbursement alignment, and specialist treatment capacity.
Latin America Focused Ultrasound Systems Market Analysis
Latin America represented 4.8% of market revenue in 2025 and is projected to generate USD 43.5 million by 2035. Adoption remains concentrated in better-equipped private and university hospitals, where suppliers can support specialist clinical programs and physician education. Growth will rely on improving reimbursement mechanisms and broadening access beyond flagship institutions.
Brazil
Brazil generated USD 8.3 million in 2025 and is expected to account for 44.8% of Latin American market revenue by 2035. Its advanced hospital sector and large private healthcare market provide a foundation for focused ultrasound deployment. Expansion will depend on whether public procurement processes and private health operator investment extend access beyond major urban referral centers.
Mexico
Mexico represented 27.1% of Latin American market revenue in 2025 and is projected to grow at a 9.5% CAGR (2026-2035). The country combines private hospital purchasing capacity with proximity to U.S. training and commercial networks. This creates a meaningful opportunity for suppliers that can develop urology and gynecology referral pathways alongside equipment sales.
Argentina
Argentina and other Latin American markets are developing through isolated academic placements and private specialty clinics. Regulatory registration, physician awareness, and localized service capability will determine whether early installations become repeatable commercial programs.
Middle East & Africa Focused Ultrasound Systems Market Analysis
Middle East & Africa generated USD 14.3 million in 2025 and is projected to grow at an 11.2% CAGR (2026-2035). The focused ultrasound systems market is supported primarily by Gulf health systems investing in tertiary care infrastructure and premium medical technology. Adoption is expected to remain concentrated in major referral institutions, although government-led procurement can accelerate market entry when strategic priorities align.
Saudi Arabia
Saudi Arabia generated USD 4.8 million in 2025 and is projected to grow at an 11.8% CAGR (2026-2035). Demand is concentrated in tertiary hospitals and private facilities participating in healthcare modernization programs. The market's progression depends on procurement decisions, specialist training, and the development of sustainable referral pathways for neurological, gynecological, and urological applications.
UAE
The UAE represented 29.4% of Middle East & Africa market revenue in 2025 and is projected to generate USD 13.2 million by 2035. Its medical tourism position, specialist physician base, and premium-technology procurement orientation support adoption of both MR-guided and therapeutic HIFU systems. The country can also function as a regional reference market for providers seeking exposure to non-invasive treatment platforms.
South Africa
South Africa provides the region's most established sub-Saharan demand base through placements at leading private hospital groups. Further development will depend on specialist capacity, reimbursement conditions, and the availability of service support.
Rest of MEA
Other Middle East & Africa markets remain at an early adoption stage. Hospital infrastructure investment, regulatory registration, and clinical awareness programs are the principal near-term factors that may enable new market entry.
GMI Analyst View
We expect regional performance to be determined less by a uniform technology-adoption curve than by local reimbursement, procurement, and clinical-capacity conditions. Mature markets can deepen utilization within existing care networks, while emerging markets may add capacity through first-time installations. Suppliers therefore need distinct commercial models for reimbursement-led expansion, public procurement opportunities, and clinician-training-intensive market entry.
Focused Ultrasound Systems Market Share & Competitive Landscape
The focused ultrasound systems market exhibits a moderately to highly concentrated competitive structure, with Insightec, Chongqing Haifu Medical Technology, EDAP TMS, Profound Medical, and SonaCare Medical (Sonablate) collectively accounting for approximately 63.1% of global market revenue in 2025. Market competition is driven by technological differentiation across MR-guided and ultrasound-guided platforms, clinical evidence generation, reimbursement expansion, physician training, and installed-base support. Leading companies are focused on broadening the clinical utility of focused ultrasound through new indications in neurology, oncology, urology, gynecology, and aesthetic medicine, while also improving accessibility through portable and lower-cost platform configurations.
Other notable participants include BrainSonix, EpiSonic, FUSMobile, ILJIN Holdings, Lynton Lasers, Theraclion, Ultraiser, and Verasonics, which compete through specialized focused ultrasound technologies across neuromodulation research, aesthetic medicine, thyroid ablation, portable therapeutic systems, and research-focused ultrasound platforms. These companies strengthen market innovation by addressing niche clinical applications, expanding treatment accessibility, and supporting the development of emerging focused ultrasound use cases.
As the clinical adoption of focused ultrasound continues to broaden across oncology, neurology, urology, aesthetics, and other therapeutic areas, competitive differentiation is increasingly driven by clinical evidence generation, indication expansion, treatment accessibility, workflow efficiency, and platform versatility. Suppliers that can demonstrate strong clinical outcomes, support new applications, and simplify integration into existing care pathways are expected to be best positioned to capture future market growth.
Recent Industry Developments
In December 2025, Insightec announced the spin-out of Lotus Neuro establishing a clinical-stage biotechnology company focused on low-frequency focused ultrasound for brain-targeted combination therapeutics. The initiative formalizes a development pathway for blood-brain barrier opening and brain-focused therapeutic applications beyond conventional device commercialization [5]Insightec. "Multiple primary press releases, 2025–2026." insightec.com.
In October 2025, EDAP TMS entered a conditional USD 40.0 million credit facility agreement with the European Investment Bank.The facility is intended to support research and development in robotic HIFU across prostate cancer, endometriosis, and additional applications under investigation, providing development funding for the company's platform strategy [6]EDAP TMS S.A. "Form 6-K — EIB Credit Facility Agreement." sec.gov.
In November 2025, EDAP TMS received FDA 510(k) clearance for enhancements to its Focal One i system. The clearance covered imaging and workflow improvements intended to strengthen treatment visualization and procedural planning capabilities for robotic HIFU users [7]EDAP TMS S.A. "EDAP Receives FDA 510(k) Clearance for Latest Evolution Focal One." investor.edap-tms.com.
In March 2026, Insightec announced national reimbursement in France for unilateral MR-guided focused ultrasound treatment of medication-refractory essential tremor. The reimbursement milestone provides a clearer pathway for hospital access to the procedure within France's health insurance framework [5]Insightec. "Multiple primary press releases, 2025–2026." insightec.com.
In February 2026, Insightec received a Health Canada Medical Device License for the Exablate Prime system. The approval expands the system's access pathway for essential tremor treatment and broadens compatibility with select MRI platforms used by Canadian academic hospitals [5]Insightec. "Multiple primary press releases, 2025–2026." insightec.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →